Aflivu
Aflibercept biosimilar developed by Apotex. Reference product Eylea.
Brands by market: Aflivu (Canada) · Commercial partner or holder: Apotex · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCJun 2025approved
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Aflivu
Aflivu is Apotex's aflibercept, approved in Canada in June 2025. It is a Canadian product with no counterpart in the United States or Europe, and Apotex has not named the developer.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada · Aflivu
Health CanadaApprovedBrand
Aflivu
Holder or applicant
Apotex INC
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Jun 2025
Application or permission
DIN 02554178, 02554194
Presentations
2 mg
Source
S022 (Health Canada) · checked Sep 2026
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Aflivu holds an approval, these are the other aflibercept biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| HC | 4 | Amgen (Pavblu), Biocon Biologics (Yesafili), Celltrion (Eydenzelt), Sandoz (Enzeevu / Afqlir) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Apotex: Bambevi, Denoza.
Chronology
- HCJun 2025Notice of Compliance, Health Canada
Sources
Planning aflibercept biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.